Dichloromethotrexate - A critical reassessment

P. J. O'Dwyer; B. Leyland-Jones; M. T. Alonso; M. Eisenberger; D. F. Hoth

doi:10.1200/JCO.1985.3.8.1148

Dichloromethotrexate - A critical reassessment

P. J. O'Dwyer, B. Leyland-Jones, M. T. Alonso, M. Eisenberger, D. F. Hoth

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

We review the biochemical, pharmacologic, and clinical evidence, which indicates that dichloromethotrexate (DCMTX) may in certain circumstances display a therapeutic advantage over the parent compound methotrexate (MTX); studies are suggested to clarify the role of DCMTX in the clinic.

Original language	English (US)
Pages (from-to)	1148-1153
Number of pages	6
Journal	Journal of Clinical Oncology
Volume	3
Issue number	8
DOIs	https://doi.org/10.1200/JCO.1985.3.8.1148
State	Published - Jan 1 1985
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.1985.3.8.1148

Cite this

@article{dd06393eb7e74dd380fc14a5c10ebc64,

title = "Dichloromethotrexate - A critical reassessment",

abstract = "We review the biochemical, pharmacologic, and clinical evidence, which indicates that dichloromethotrexate (DCMTX) may in certain circumstances display a therapeutic advantage over the parent compound methotrexate (MTX); studies are suggested to clarify the role of DCMTX in the clinic.",

author = "O'Dwyer, {P. J.} and B. Leyland-Jones and Alonso, {M. T.} and M. Eisenberger and Hoth, {D. F.}",

year = "1985",

month = jan,

day = "1",

doi = "10.1200/JCO.1985.3.8.1148",

language = "English (US)",

volume = "3",

pages = "1148--1153",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "8",

}

TY - JOUR

T1 - Dichloromethotrexate - A critical reassessment

AU - O'Dwyer, P. J.

AU - Leyland-Jones, B.

AU - Alonso, M. T.

AU - Eisenberger, M.

AU - Hoth, D. F.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - We review the biochemical, pharmacologic, and clinical evidence, which indicates that dichloromethotrexate (DCMTX) may in certain circumstances display a therapeutic advantage over the parent compound methotrexate (MTX); studies are suggested to clarify the role of DCMTX in the clinic.

AB - We review the biochemical, pharmacologic, and clinical evidence, which indicates that dichloromethotrexate (DCMTX) may in certain circumstances display a therapeutic advantage over the parent compound methotrexate (MTX); studies are suggested to clarify the role of DCMTX in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=0022253923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022253923&partnerID=8YFLogxK

U2 - 10.1200/JCO.1985.3.8.1148

DO - 10.1200/JCO.1985.3.8.1148

M3 - Article

C2 - 4020413

AN - SCOPUS:0022253923

SN - 0732-183X

VL - 3

SP - 1148

EP - 1153

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 8

ER -

Dichloromethotrexate - A critical reassessment

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this